# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Charles Darwin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI003-SYN
- Date: 2026-09-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Bernard Ashworth, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review of cyclic vomiting syndrome. **S**

## History of present illness

Mr. Darwin returns after three months at amitriptyline 75 mg at bedtime. He has had one episode in that time, three weeks ago, after an overnight journey with little sleep. He used the sumatriptan spray and an ondansetron tablet at the first nausea and trembling, lay down in a dark room, and was well again within about four hours, without vomiting more than twice. He has had no emergency visits. The dry mouth persists, the constipation is better with more fluid and fiber, and the morning grogginess has faded. He walks most days, practices the relaxation breathing most evenings, and has accepted more invitations than in the spring. He still has some wind between episodes, which troubles him less. **S**

| Element | Detail |
|---|---|
| Medicine | Amitriptyline 75 mg at bedtime for three months at the target dose |
| Episodes | One brief episode in three months, after overnight travel, aborted within about four hours |
| Side effects | Dry mouth; constipation improved; grogginess gone |
| Function | Working most days; going out more |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Wind between episodes, less troublesome; one brief episode; constipation improved |
| Ears, nose, mouth, and throat | Positive | Dry mouth |
| Cardiovascular | Negative | No palpitations outside the prodrome; no fainting |
| Psychiatric | Negative | Mood good; worry about episodes much less; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Amitriptyline 75 mg oral tablet, one tablet at bedtime **S**
- Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode **S**
- Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 72.9 kg; BMI 21.8 kg/m². All vital signs are synthetic.

GAD-7: 5; PHQ-9: 3. All results are synthetic.

## Change since baseline

- GAD-7: 8 at baseline, 5 at this visit **S**
- PHQ-9: 6 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and relaxed; weight 72.9 kg |
| Cardiovascular | Regular rhythm at 70 per minute; blood pressure 116/72 mmHg |
| Abdomen | Soft and non-tender |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cyclic vomiting syndrome, provisional** (R11.15). Good response to prophylaxis: one brief, aborted episode in three months at the target dose, against about two a month before treatment, which is more than a 50 percent reduction. Side effects are tolerable and the weight gain is 1.5 kg since treatment began. The diagnosis remains clinical and provisional; no new feature has appeared to suggest another cause. **S**
   - Continue amitriptyline 75 mg at bedtime for at least a year, then consider a slow taper if he stays well.
   - Continue the abortive plan and carry the emergency department letter.
   - Plan for travel: sleep the night before when possible, regular meals, and the abortive medicines in his hand luggage.
   - Review in three months, or sooner for more frequent or longer episodes.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Episode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed work | Every visit | Completed today | One episode in three months, about four hours, aborted at the prodrome; no emergency visits |
| Examination | Rome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50) | At diagnosis and with any change in pattern | Completed today | Pattern unchanged and milder; no red flags |
| Laboratory | Blood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serology | At diagnosis between episodes; repeat only for an atypical episode | Up to date | Normal at diagnosis; no atypical episode |
| Imaging | Upper endoscopy and small-bowel imaging (CT enterography) | Once at diagnosis | Up to date | Normal at diagnosis |
| Imaging | Gastric emptying study | Not routine; only between episodes when gastroparesis is suspected | Not indicated | No symptoms of gastroparesis |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Up to date | QTc 436 ms at 75 mg three months ago; repeat only with a dose change or a new QT-prolonging medicine |
| Medication safety | Amitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weight | Each visit on treatment | Completed today | Dry mouth persists; constipation and grogginess improved; weight 72.9 kg (up 1.5 kg since starting) |
| Survey | Mood and thoughts of self-harm on a tricyclic (PHQ-9) | Each visit on treatment | Completed today | PHQ-9 3, with item 9 scored 0 |
| Survey | Anxiety screen (GAD-7) | At diagnosis, then every three months | Completed today | GAD-7 5, down from 8 at the first visit |
| Medication safety | Abortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limits | Every visit | Completed today | Used once, at the prodrome, with relief in about four hours; within dose limits |
| Self-management | Individualized emergency department protocol letter | At diagnosis; update with any change in treatment | Up to date | Letter carried; no change in treatment, so no update needed |
| Self-management | Triggers: sleep, meals, travel, social stress, infections | Every visit | Completed today | Overnight travel with short sleep triggered the one episode; a travel plan agreed |
| Self-management | Cannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome) | At diagnosis and yearly | Up to date | No cannabis use; recheck yearly |
| Examination | Comorbidities: migraine, orthostatic and autonomic symptoms, sleep disorders | At diagnosis and yearly | Up to date | No migraine, orthostatic symptoms, or sleep disorder |
| Medication safety | Mitochondrial supplements (coenzyme Q10, riboflavin) | Conditional; consider with a partial response | Not indicated | Good response to amitriptyline |
| Medication safety | Alternative prophylaxis (topiramate or aprepitant) | Only if amitriptyline fails or is not tolerated | Not indicated | Amitriptyline effective and tolerated |
| Self-management | Relaxation training, meditation, or biofeedback; cognitive behavioral therapy offered | Ongoing | Completed today | Breathing practice most evenings; he does not want cognitive behavioral therapy now, and the offer stays open |
| Examination | Weight and hydration | Every visit | Completed today | 72.9 kg; well hydrated |

## Goal progress

- Complete the work-up between episodes (blood and urine tests, ECG, CT enterography, and upper endoscopy) before the six-week visit. Outcome by 2026-04-14: All tests normal; Rome IV criteria met; provisional diagnosis of cyclic vomiting syndrome at the consultation. **S**
- At least half as many episodes after three months at the target dose of prophylaxis. Outcome by 2026-09-08: About two episodes a month before treatment; one brief episode, aborted at the prodrome, in the three months before the six-month review. **S**
- Carry the abortive medicines and the emergency department letter, and use them at the prodrome. Outcome by 2026-06-09: The one episode since starting treatment was treated at the prodrome and settled in about ten hours without an emergency visit; letter carried. **S**
- QTc below 450 ms at the target amitriptyline dose. Outcome by 2026-06-09: QTc 436 ms on 75 mg. **S**
- Practice relaxation breathing most days and lower the GAD-7 score by the six-month review. Outcome by 2026-09-08: Daily breathing practice; GAD-7 from 8 to 5. **S**

## Guideline basis

- Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019), American Neurogastroenterology and Motility Society and Cyclic Vomiting Syndrome Association (Neurogastroenterology & Motility)
- Anxiety Disorders in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Review in three months; at one year, discuss a slow taper of amitriptyline if he stays well. **S**

